{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:06:23Z","timestamp":1784934383914,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ekir.2025.02.028","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T11:36:29Z","timestamp":1741001789000},"page":"1468-1475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists"],"prefix":"10.1016","volume":"10","author":[{"given":"Edouard","family":"Cubilier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youcef","family":"Chergui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Garrouste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Philipponnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Atenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarisse","family":"Greze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Aniort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Uro-Coste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Elisabeth","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.02.028_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.02.028_bib2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.10131011","article-title":"Epidemiology and pathophysiology of nephrotic syndrome\u2013associated thromboembolic disease","volume":"7","author":"Kerlin","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.02.028_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.102162","article-title":"Thromboembolism in nephrotic syndrome: Controversies and uncertainties","volume":"7","author":"Parker","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ekir.2025.02.028_bib4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.thromres.2021.02.007","article-title":"Nephrotic syndrome disease activity is proportional to its associated hypercoagulopathy","volume":"201","author":"Waller","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.ekir.2025.02.028_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2215\/CJN.0000000000000054","article-title":"Understanding hypercoagulability with nephrotic syndrome: How the clot thickens","volume":"18","author":"Greenberg","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.02.028_bib6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJMcibr1209459","article-title":"Venous thrombosis in the nephrotic syndrome","volume":"368","author":"Loscalzo","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.02.028_bib7","first-page":"739","article-title":"Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study","volume":"15","author":"Zhang","year":"2018","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.ekir.2025.02.028_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2024.0794","article-title":"Thromboembolic phenomena in patients with nephrotic syndrome: Pathophysiology, risk factors, prophylaxis and treatment","volume":"85","author":"Wang","year":"2024","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.ekir.2025.02.028_bib9","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1681\/ASN.2006111300","article-title":"Prophylactic anticoagulation in nephrotic syndrome: A clinical conundrum: A clinical conundrum","volume":"18","author":"Glassock","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.02.028_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: Membranous nephropathy-A modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.02.028_bib11","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ekir.2018.02.010","article-title":"Direct-acting oral anticoagulants as prophylaxis against thromboembolism in the nephrotic syndrome","volume":"3","author":"Sexton","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.02.028_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255009","article-title":"Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome-A retrospective observational study","volume":"16","author":"Welander","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2025.02.028_bib13","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1055\/a-1920-6224","article-title":"Apixaban prophylactic anticoagulation in patients with nephrotic syndrome","volume":"6","author":"Van Meerhaeghe","year":"2022","journal-title":"TH Open"},{"key":"10.1016\/j.ekir.2025.02.028_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.ajkd.2022.09.011","article-title":"Pharmacokinetics and pharmacodynamics of apixaban in nephrotic syndrome: Findings from a phase 1a trial","volume":"81","author":"Derebail","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.02.028_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000535546","article-title":"Anticoagulation in patients with chronic kidney disease","volume":"55","author":"Elenjickal","year":"2024","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2025.02.028_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2215\/CJN.05250419","article-title":"Prophylactic anticoagulation in adult patients with nephrotic syndrome","volume":"15","author":"Gordon-Cappitelli","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.02.028_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12882-019-1336-8","article-title":"Prophylactic anticoagulation in nephrotic syndrome prevents thromboembolic complications","volume":"20","author":"Kelddal","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.02.028_bib18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12882-022-02929-x","article-title":"Safety and effectiveness of direct oral anticoagulants in patients with nephrotic syndrome: A report of 21 cases","volume":"23","author":"Kelddal","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.02.028_bib19","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1177\/10600280221129348","article-title":"Direct oral anticoagulants versus warfarin for venous thromboembolism prophylaxis in patients with nephrotic syndrome: A retrospective cohort study","volume":"57","author":"Tijani","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2025.02.028_bib20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in atrial fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2025.02.028_bib21","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ekir.2025.02.028_bib22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ekir.2025.02.028_bib23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925001184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925001184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T23:18:40Z","timestamp":1752794320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925001184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2468024925001184"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.02.028","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nephrotic Syndrome Thromboprophylaxis With Direct Oral Anticoagulants or Vitamin K Antagonists","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}